TScan Therapeutics, Inc. (TCRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on May 20, 2026, specifically the Company's 2026 Annual Meeting of Stockholders. TScan Therapeutics, Inc., a Delaware corporation, reported the outcomes of four proposals submitted to its stockholders.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Corporate Actions
- Authorized Share Increase: Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation, increasing the number of authorized shares of voting common stock from 300,000,000 to 600,000,000. The Certificate of Amendment was filed with the Delaware Secretary of State and became effective immediately.
- Director Elections: Katina Dorton, J.D., M.B.A., and R. Keith Woods were elected as Class II directors for three-year terms ending in 2029.
- Accounting Firm Ratification: Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Voting Results
| Proposal | Votes For | Votes Against/Withheld | Broker Non-Votes |
|---|---|---|---|
| Election of Katina Dorton | 19,665,447 | 4,508,811 (Withheld) | 15,247,179 |
| Election of R. Keith Woods | 23,305,311 | 868,947 (Withheld) | 15,247,179 |
| Ratification of Auditors | 38,497,976 | 637,978 (Against) | 15,247,179 |
| Share Authorization Amendment | 35,913,605 | 3,177,381 (Against) | 15,247,179 |
| Adjournment Proposal | 21,897,635 | 2,007,636 (Against) | 15,247,179 |
Outlook, Risks, and Management Commentary
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The document notes that the description of the Certificate of Amendment is qualified by reference to the full text filed as Exhibit 3.1.
Key Facts for Investor Verification
- Verify the impact of the 100% increase in authorized shares (from 300M to 600M) on potential future dilution.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 17, 2026) for detailed biographies of the newly elected directors and the rationale for the share increase.
- Confirm the effective date of the Certificate of Amendment with the Delaware Secretary of State records.
- Note that 15,247,179 broker non-votes were recorded across all proposals, indicating a significant portion of shares held in street name where brokers lacked discretionary voting power.